Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial

Ravi Ramessur; Zelma C. Chiesa Fuxench; Daniel Shin; Jennifer B. Mason; Anabel C. Mason; Maryte Papadopoulos; Bruna Galvao de Oliveira Wafae; Megan H. Noe; Joel M. Gelfand

PMC · DOI:10.1016/j.jdin.2025.09.015·October 9, 2025

Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial

Ravi Ramessur, Zelma C. Chiesa Fuxench, Daniel Shin, Jennifer B. Mason, Anabel C. Mason, Maryte Papadopoulos, Bruna Galvao de Oliveira Wafae, Megan H. Noe, Joel M. Gelfand

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Chemicals1

Deucravacitinib

Diseases1

palmoplantar pustulosis

Figures1

Click any figure to enlarge with its caption.

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsDrug-Induced Adverse Reactions · Urticaria and Related Conditions · Dupuytren's Contracture and Treatments